FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on protocol VP-VLY-686-3403, which until today limited the protocol to a maximum of 90 doses of tradipitant. https://mma.prnewswire.com/media/2090054/VandaLogo_v1.jpg The lift followed Vanda's formal dispute resolution request and an expedited re-review conducted by CDER leadership […]